相关实验视频
Updated: May 10, 2025

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
在Orlistat使用后探索急性胰腺炎:一个案例报告
Abeer Qasim1, Abhilasha Jyala1, Ornela Thartori1
1Internal Medicine, BronxCare Health System, Bronx, USA.
作为肥胖症的脂酶抑制剂,奥利斯塔特可能与急性胰腺炎有关. 本案例研究和文献综述探讨了使用这种常见药物的患者的这种潜在不良事件.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 临床案例研究 临床案例研究
背景情况:
- 奥利斯塔特是一种FDA批准的胰腺脂酶抑制剂,用于肥胖管理.
- 它在许多国家广泛无处置,导致使用率增加.
- 越来越多的利用需要对潜在的不良事件有全面的了解.
研究的目的:
- 调查奥利斯塔特治疗与急性胰腺炎的发展之间的关联.
- 分析临床病例并确定这种不良事件的潜在风险因素.
- 为了解奥利斯塔特和急性胰腺炎表现之间的相关性提供见解.
主要方法:
- 一个23岁的女性在开始服用奥利斯塔特后出现急性胰腺炎的病例报告.
- 对医学文献和现有病例研究进行系统审查.
- 对临床数据和与Orlistat使用相关的潜在风险因素的分析.
主要成果:
- 该研究描述了一个特定的案例,将Orlistat使用与急性胰腺炎联系起来.
- 用文献审查和案例分析来探索相关性.
- 研究了潜在的风险因素和关联的性质.
结论:
- 奥利斯塔特治疗可能与急性胰腺炎的风险增加有关.
- 需要进一步的研究,以充分阐明奥利斯塔特与胰腺炎的联系.
- 对于临床医生和患者来说,意识到这种潜在的不良事件至关重要.
更多相关视频
07:10Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
相关概念视频
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis II: Collaborative Care
Assessment: